Suppr超能文献

2019 冠状病毒病患者的器官功能支持:同济经验。

Organ function support in patients with coronavirus disease 2019: Tongji experience.

机构信息

Department of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Department of Nephrology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

出版信息

Front Med. 2020 Apr;14(2):232-248. doi: 10.1007/s11684-020-0774-9. Epub 2020 May 14.

Abstract

Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.

摘要

新型冠状病毒肺炎(COVID-19)是一种高传染性疾病,严重威胁人类健康。COVID-19 可引起多器官功能障碍,如呼吸和循环衰竭、肝肾功能损伤、弥散性血管内凝血、血栓栓塞等,甚至死亡。世界卫生组织报告称,重型 COVID-19 的死亡率超过 50%。目前,全球重型病例数量迅速增加,但感染患者的治疗经验仍有限。鉴于缺乏特效抗病毒药物,多器官功能支持治疗对 COVID-19 患者非常重要。为提高重型和危重型 COVID-19 患者的治愈率,降低死亡率,本文总结了中国武汉同济医院光谷院区重型和危重型 COVID-19 患者的器官功能支持治疗经验。本文系统总结了重型和危重型 COVID-19 患者呼吸、循环、肾、肝、血液等多器官和系统功能支持治疗的流程,为全球 COVID-19 的最佳治疗提供了临床参考和新策略。

相似文献

1
Organ function support in patients with coronavirus disease 2019: Tongji experience.
Front Med. 2020 Apr;14(2):232-248. doi: 10.1007/s11684-020-0774-9. Epub 2020 May 14.
3
Surviving 2019 novel coronavirus pneumonia: A successful critical case report.
Heart Lung. 2020 Nov-Dec;49(6):692-695. doi: 10.1016/j.hrtlng.2020.08.009. Epub 2020 Aug 20.
5
Pathophysiology and treatment strategies for COVID-19.
J Transl Med. 2020 Sep 15;18(1):353. doi: 10.1186/s12967-020-02520-8.
6
COVID-19 challenge for modern medicine.
Cardiol J. 2020;27(2):175-183. doi: 10.5603/CJ.a2020.0055. Epub 2020 Apr 14.
7
Treatment considerations for coronavirus (COVID-19).
Hosp Pract (1995). 2020 Aug;48(3):119-120. doi: 10.1080/21548331.2020.1754618. Epub 2020 Apr 13.
8
Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.
Eur Rev Med Pharmacol Sci. 2020 Aug;24(15):8194-8201. doi: 10.26355/eurrev_202008_22508.
10
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.
Int J Environ Res Public Health. 2020 Mar 30;17(7):2323. doi: 10.3390/ijerph17072323.

引用本文的文献

1
Thyroid Dysfunction among the Patients with Critical COVID-19.
Infect Dis Clin Microbiol. 2022 Dec 21;4(4):229-235. doi: 10.36519/idcm.2022.175. eCollection 2022 Dec.
2
Study of thyroid function among COVID-19-affected and non-affected people during pre and post-vaccination.
BMC Endocr Disord. 2022 Dec 9;22(1):309. doi: 10.1186/s12902-022-01187-0.
3
Assessment of thyroid function of newly diagnosed SARS-CoV-2 infected patients in Nigeria.
Pan Afr Med J. 2021 Sep 2;40:9. doi: 10.11604/pamj.2021.40.9.26358. eCollection 2021.
4
Liver injury in COVID-19: Known and unknown.
World J Clin Cases. 2021 Jul 6;9(19):4980-4989. doi: 10.12998/wjcc.v9.i19.4980.
7
Thyroid Function Abnormalities in COVID-19 Patients.
Front Endocrinol (Lausanne). 2021 Feb 19;11:623792. doi: 10.3389/fendo.2020.623792. eCollection 2020.
10
COVID-19 and Thyroid: Progress and Prospects.
Int J Environ Res Public Health. 2020 Sep 11;17(18):6630. doi: 10.3390/ijerph17186630.

本文引用的文献

2
[Chinese experts' consensus on diagnosis and treatment of severe and critical coronavirus disease 2019 (revised edition)].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Mar;32(3):269-274. doi: 10.3760/cma.j.cn121430-20200218-00188.
5
[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. doi: 10.3760/cma.j.issn.1001-0939.2020.03.008.
8
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
9
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
10
First Case of 2019 Novel Coronavirus in the United States.
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验